Mizuho Trust & Banking’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mizuho Trust & Banking’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-116,342	Closed	-$7.89M	–	46
2016 Q3	$7.89M	Hold	116,342	–	–	0.02%	580
2016 Q2	$6.46M	Sell	116,342 -4,369	-4%	-$275K	0.02%	607
2016 Q1	$7.58M	Buy	120,711 +3,365	+3%	+$224K	0.02%	586
2015 Q4	$11.1M	Buy	117,346 +5,796	+5%	+$537K	0.04%	492
2015 Q3	$8.96M	Buy	111,550 +6,683	+6%	+$743K	0.03%	548
2015 Q2	$12.6M	Buy	+104,867	New	+$12.5M	0.04%	470

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mizuho Trust & Banking's ALNY Position: Q4 2016 in Review

Mizuho Trust & Banking sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 116,342 shares — an estimated $7.89M sold.

Mizuho Trust & Banking first reported a position in ALNY in Q2 2015 and held it in 6 quarters. The position peaked at $12.6M in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Mizuho Trust & Banking reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Mizuho Trust & Banking sold 116,342 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $7.89M.
Mizuho Trust & Banking first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Mizuho Trust & Banking's Alnylam Pharmaceuticals position peaked at $12.6M in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Mizuho Trust & Banking's 13F filing for Q4 2016, filed 14 Feb 2017.